If the p2 results are expected next month then zlcs will do an other issue. Why? In the last balance sheet there was 22 million in current assets and 17 million in current liabilities. That leaves 5 mill free. The annuaul negative cash flow is negative 38 million. They will have to do another issue soon. They have about a quarter of cash left.
it will be interesting to see it the wait until the results are published.
other bios i have been in when they do it gives you a good indication of the result.
if they do it before the results they are telling you the results are bad.
why? Because they now if the result are good the price will be 10 to 15. Why do a new issue at 4.75 -- why not wait to do it post results.
so watch for it.
HERE IS THEIR 2013 JUNE BS. SEE IF YOU CAN PICK OUT THE
TOTAL CURRENT ASSETS AND LIABLIITIES. FIRST TIME IN AND
I ALWAYS GET THE BOART D/HD TO RESPOND JUST LUCKY I GUESS.
Cash And Cash Equivalents 2,914 3,271 4,581 8,971
Short Term Investments 16,115 21,077 30,059 34,265
Net Receivables 2,329 2,532 3,045 3,098
Inventory - - - -
Other Current Assets 1,040 834 684 1,039
Total Current Assets 22,398 27,714 38,369 47,373
Long Term Investments - - - -
Property Plant and Equipment 3,016 3,212 3,535 3,869
Goodwill - - - -
Intangible Assets 13,293 15,473 17,654 18,627
Accumulated Amortization - - - -
Other Assets 1,803 1,804 1,817 1,816
Deferred Long Term Asset Charges - - - -
Total Assets 40,510 48,203 61,375 71,685
Accounts Payable 6,668 4,945 8,102 8,281
Short/Current Long Term Debt 6,721 6,521 6,327 6,137
Other Current Liabilities 4,106 4,867 5,202 5,401
Total Current Liabilities 17,495 16,333 19,631
They haven't hid the possibility. On their own website, they said one of the benefits of the r/s is they're still authorized to issue the same number of shares of stock. So, on paper that allowed them to raise up to 6 times as much money as they could have previously by issueing more stock. Cash flow is a concern.
You are forgetting they have other assets, such as business opportunity and exclusivity that are highly valued in their own right by bidders for collaborations. Non of that need have ANY involvement with the stock.